Early and Complete Response of Bone Metastases, Documented by FDG-PET/CT Scan, in a Patient With NSCLC

Overview

Journal World J Oncol

Specialty Oncology

Date 2017 Nov 18

PMID 29147277

Authors

David Rossi

Paolo Giordani

Paolo Alessandroni

Vincenzo Catalano

Virginia Casadei

Anna Maria Baldelli

Stefano Luzi Fedeli

Francesco Graziano

Giammaria Fiorentini

Affiliations

Soon will be listed here.

Abstract

In this case report we describe the case of a patient with multiple bone metastases of NSCLC, adenocarcinoma with exon 21 point-mutation of EGFR, treated with gefitinib. After only 3 months, FDG-PET/CT scan showed a complete response of bone metastases and right hylar adenopathy. Implications for need of early use of FDG-PET/CT scan after gefitinib treatment are discussed.

References

Coleman R . Skeletal complications of malignancy. Cancer. 1997; 80(8 Suppl):1588-94. DOI: 10.1002/(sici)1097-0142(19971015)80:8+<1588::aid-cncr9>3.3.co;2-z. View

Maemondo M, Inoue A, Kobayashi K, Sugawara S, Oizumi S, Isobe H . Gefitinib or chemotherapy for non-small-cell lung cancer with mutated EGFR. N Engl J Med. 2010; 362(25):2380-8. DOI: 10.1056/NEJMoa0909530. View

Zampa G, Moscato M, Brannigan B, Morabito A, Bell D, Normanno N . Prolonged control of bone metastases in non-small-cell lung cancer patients treated with gefitinib. Lung Cancer. 2007; 60(3):452-4. DOI: 10.1016/j.lungcan.2007.11.002. View

Portilla-Quattrociocchi H, Banzo I, Martinez-Rodriguez I, Quirce R, Jimenez-Bonilla J, de Arcocha Torres M . [Evaluation of bone scintigraphy and (18)F-FDG PET/CT in bone metastases of lung cancer patients]. Rev Esp Med Nucl. 2011; 30(1):2-7. DOI: 10.1016/j.remn.2010.10.005. View

Normanno N, De Luca A, Aldinucci D, Maiello M, Mancino M, DAntonio A . Gefitinib inhibits the ability of human bone marrow stromal cells to induce osteoclast differentiation: implications for the pathogenesis and treatment of bone metastasis. Endocr Relat Cancer. 2005; 12(2):471-82. DOI: 10.1677/erc.1.00956. View

Sugiura H, Yamada K, Sugiura T, Hida T, Mitsudomi T . Predictors of survival in patients with bone metastasis of lung cancer. Clin Orthop Relat Res. 2008; 466(3):729-36. PMC: 2505203. DOI: 10.1007/s11999-007-0051-0. View

Garfield D . Increasing osteoblastic lesions as a manifestation of a major response to gefitinib. J Thorac Oncol. 2007; 1(8):859-60. View

Su H, Bodenstein C, Dumont R, Seimbille Y, Dubinett S, Phelps M . Monitoring tumor glucose utilization by positron emission tomography for the prediction of treatment response to epidermal growth factor receptor kinase inhibitors. Clin Cancer Res. 2006; 12(19):5659-67. DOI: 10.1158/1078-0432.CCR-06-0368. View

Li Y, Chang J, Chou W, Liaw C, Wang H, Huang J . Zoledronic acid is unable to induce apoptosis, but slows tumor growth and prolongs survival for non-small-cell lung cancers. Lung Cancer. 2007; 59(2):180-91. DOI: 10.1016/j.lungcan.2007.08.026. View

10.

Mitsudomi T, Morita S, Yatabe Y, Negoro S, Okamoto I, Tsurutani J . Gefitinib versus cisplatin plus docetaxel in patients with non-small-cell lung cancer harbouring mutations of the epidermal growth factor receptor (WJTOG3405): an open label, randomised phase 3 trial. Lancet Oncol. 2009; 11(2):121-8. DOI: 10.1016/S1470-2045(09)70364-X. View

11.

Zhu J, Jia X, Xiao G, Kang Y, Partridge N, Qin L . EGF-like ligands stimulate osteoclastogenesis by regulating expression of osteoclast regulatory factors by osteoblasts: implications for osteolytic bone metastases. J Biol Chem. 2007; 282(37):26656-26665. DOI: 10.1074/jbc.M705064200. View

12.

Kruger S, Buck A, Mottaghy F, Hasenkamp E, Pauls S, Schumann C . Detection of bone metastases in patients with lung cancer: 99mTc-MDP planar bone scintigraphy, 18F-fluoride PET or 18F-FDG PET/CT. Eur J Nucl Med Mol Imaging. 2009; 36(11):1807-12. DOI: 10.1007/s00259-009-1181-2. View

13.

Zukawa M, Nakano M, Hirano N, Mizuhashi K, Kanamori M . The effectiveness of gefitinib on spinal metastases of lung cancer - report of two cases -. Asian Spine J. 2010; 2(2):109-13. PMC: 2852086. DOI: 10.4184/asj.2008.2.2.109. View

14.

Weber K, Doucet M, Price J, Baker C, Kim S, Fidler I . Blockade of epidermal growth factor receptor signaling leads to inhibition of renal cell carcinoma growth in the bone of nude mice. Cancer Res. 2003; 63(11):2940-7. View